Ludwig Institute, Royal Melbourne Hospital and Western Hospital, Australia.
Dr. Peter Gibbs is a physician-scientist with colorectal cancer (CRC) expertise and lead research across the spectrum from CRC prevention and screening to optimizing the treatment of advanced disease. He has supported a broad range of translational research endeavors and has more than 10 years of comprehensive treatment and outcome data for consecutive patients with CRC across five clinical centers. His international collaborations include the Bert Vogelstein group at the Ludwig Center at Johns Hopkins, with which Associate Professor Gibbs is exploring the utility of circulating tumor DNA for CRC screening as a marker of residual disease in the adjuvant setting and to guide treatment of patients with advanced disease. Associate Professor Gibbs is a lead investigator for the ASPREE study, randomizing 19,000 elderly patients to five years of low-dose aspirin versus placebo. Largely funded by the NIH ($50 million) this study seeks to define the role of aspirin as a cancer chemopreventive. He is also the lead investigator for multiple phase III clinical trials, including selective internal radiation therapy in the first line treatment of patients with colorectal cancer liver metastases, and studies of delivering irinotecan chemotherapy with hyaluronic acid with potential for both survival and toxicity benefits. Dr. Gibbs also leads an industry-sponsored registry collecting data on 2,500 consecutive patients with newly diagnosed metastatic colorectal cancer at 20 Australian, which is being used to study variations in care and outcomes and to further inform optimal care of patients with advanced CRC.